Chief Financial Officer
On April 1, 2016, Daniel Apel became CFO of Bayer in the U.S. As CFO, Daniel is a member of the U.S. Leadership Team (formerly Country Council) led by Phil Blake, Senior Bayer Representative in the U.S. and Region Head of Bayer Pharmaceuticals for the Americas.
Previously, from 2009 to 2015, Daniel was Chief Administrative Officer for Bayer HealthCare in the U.S.
With over 20 years in the life sciences industry, Daniel has held various positions of increasing leadership within Bayer’s financial community, including serving as global Head of Accounting and Reporting for Bayer Healthcare, as well as CFO/CAO for Bayer Inc. in Canada. In these positions, Daniel was pleased to oversee aspects of a number of transformative acquisitions, in- and out-licensing deals, divestitures and restructurings, among them the acquisitions of Schering AG and Dyrevo AG, the divestiture of Bayer Diagnostics and the out-licensing of the liquid tumor business. Most recently, Daniel oversaw a number of aspects of the Merck Integration and the carve-out of the Diabetes Care business.
Daniel has been a Trustee for the Healthcare Institute of New Jersey. He currently also serves as a Board member for BIO, the Biotechnology Innovation Organization.
Daniel received a BA in Economics from the University of Pennsylvania and MBA from the University of California at Berkeley. Daniel also has active designations as a Certified Financial Planner and a Certified Public Accountant.